Immunological approaches to the purification of putative premalignant hepatocytes from genotypic mosaic rat livers.

Surface-localized rat RT1 alloantigens on isolated hepatocytes have been used to achieve partial purification of putative premalignant liver cells from rats undergoing chemically induced hepatocarcinogenesis. Genotypic mosaic rat livers were constructed by transplantation of carcinogen-altered F-344 (RT1Iv1) or WF (RT1u) donor liver cells into livers of WF X F-344 F1 host rats, whose liver cells bear alloantigens of both parental strains: WF and F-344, RT1u and RT1Iv1, respectively (J. M. Hunt et al., Cancer Res., 42: 227-236, 1982). Donor and host origin hepatocytes were thus distinguishable immunologically with anti-RT1u or anti-RT1Iv1 alloantisera. Donor rats were treated with diethylnitrosamine (200 mg/kg i.p.) followed by an experimental regimen of dietary 2-acetylaminofluorene and partial hepatectomy. Standard host rats received only the 2-acetylaminofluorene-partial hepatectomy regimen. At 10 to 21 days after transplantation, mosaic host rat livers typically contained 7% donor origin hepatocytes, 96% of which were positive histochemically for gamma-glutamyl transpeptidase. Host origin hepatocytes could be effectively purified by affinity chromatography ("panning") of isolated hepatocytes. To obtain donor origin hepatocytes, the putative progenitor cells of liver carcinomas in these mosaic livers, two approaches were used. Alloantibody-mediated rosette formation followed by sedimentation through Ficoll/metrizamide resulted in a 4- to 10-fold enrichment for donor origin hepatocytes isolated from mosaic livers. Similarly, a 5- to 11-fold enrichment for donor origin hepatocytes was achieved by specific alloantibody-mediated cytolysis of host hepatocytes with rabbit complement followed by purification of viable donor origin cells by sedimentation on metrizamide cushions. Hepatocellular carcinomas which developed in the genotypic mosaic host rat livers were excised 17 to 21 months after donor liver cell transplantation and passaged s.c. or i.m. in histocompatible rats. The transplantable tumors were typed for strain of origin by indirect immunofluorescence using rat alloantisera, and five of six tumors displayed antigenicity reflecting donor strain origin. We conclude, therefore, that the transplanted donor liver cell populations contain cellular precursors of hepatocellular carcinomas which may be isolable using combinations of the purification strategies described.

Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.

Moricizine (moracizine, ethmozine) is an orally active phenothiazine derivative with direct myocardial Class I antiarrhythmic activity and minimal CNS effects. Placebo-controlled studies have confirmed its efficacy in suppressing nonmalignant ventricular arrhythmias (premature ventricular complexes, couplets and runs of nonsustained ventricular tachycardia), including those refractory to previous antiarrhythmic therapy. Preliminary findings have indicated that moricizine is also effective in suppressing atrial ectopic activity, atrioventricular nodal re-entry tachycardia and Wolff-Parkinson-White tachycardias involving accessory pathways. As with other oral antiarrhythmics, malignant ventricular arrhythmias (sustained ventricular tachycardia and ventricular fibrillation) have been shown, both on noninvasive monitoring and programmed electrical stimulation, to be less susceptible to suppression by moricizine than nonmalignant ventricular arrhythmias. The therapeutic potential of moricizine is enhanced by its relatively low incidence of extra-cardiac adverse effects (predominantly gastrointestinal and neurological) and its lack of significant cardiodepressant activity in patients with normal or mildly to moderality depressed left ventricular function. Moricizine has proved to be more effective than disopyramide and propranolol in suppressing ventricular ectopic activity, of comparable efficacy to quinidine, but less effective than encainide and flecainide. The drug appears to be particularly suited to the suppression of ventricular ectopy in patients with preexisting left ventricular dysfunction. Further studies are required to confirm its long term efficacy and effects on mortality when used prophylactically in patients at increased risk of sudden cardiac death.

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.

While epidermal growth factor receptor (EGFR) dysregulation is known to play a critical role in prostate carcinogenesis, there has been no direct evidence indicating EGFR mutations induce tumorigenesis in prostate cancer. We previously identified four novel EGFR somatic mutations in the EGFR tyrosine kinase domain of prostate cancer patients: G735S, G796S, E804G and R841K. In this study, we investigated the oncogenic potential of these somatic mutations by establishing stable clonal NIH3T3 cells expressing these four mutations and WT EGFR to determine their ability to increase cell proliferation and invasion. In the absence of the EGF ligand, cell proliferation was readily increased in G735S, G796S and E804G mutants compared to WT EGFR. The addition of EGF ligand greatly increased cell growth and transforming ability of these same EGFR mutants. Matrigel invasion assays showed enhanced invasion with G735S, G796S and E804G mutants. Western blot analysis showed that these EGFR mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3) and Akt pathways. Our findings demonstrate the oncogenic activation of three novel EGFR somatic missense mutations in prostate cancer. Molecules that regulate the mechanisms of their oncogenic activation represent novel targets for limiting tumor cell progression, and further elucidation of these mutations will have utility in prostate cancer treatment.

Alloantigen-mediated adherence of rat hepatocytes to antibody-coated polystyrene dishes.

Rat alloantigens expressed on normal hepatocytes have been utilized in a cell "panning" procedure to mediate the haplotype-specific adherence of collagenase-isolated hepatocytes to antibody-coated polystyrene dishes. A polyvalent F344 anti-WF alloantiserum was prepared by immunizing F344 rats with WF tissue. The alloantibody IgG purified from the alloantiserum, when reacted with either WF or (WF X F344)F1 hybrid rat hepatocytes, caused the adherence of these hepatocytes to bacteriological-grade polystyrene dishes coated non-specifically with a xeno-antibody, rabbit anti-rat IgG. Similarly-treated hepatocytes of the F344 strain, which lack WF alloantigenic determinants, failed to be adsorbed above background level to the coated dishes.

Electrophoretic resolution of two rat class I alloantigens expressed on (WF X F344)F1 liver cells in primary culture.

Polyvalent alloantisera, prepared by reciprocal immunization of F344 (RT1lv1 haplotypes) and WF (RT1u haplotype) rats, as well as monoclonal antibodies, were used to immunoprecipitate class I alloantigens from detergent extracts of monolayer cultures of 35S-methionine-labelled liver cells. Two-dimensional IEF/SDS-PAGE gel analysis resolved the RT1.Alv1 and RT1.Au class I antigens expressed on the liver cells in culture.

The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.

The anti-inflammatory mechanism of sulfasalazine is not well understood. It has recently been shown that sulfasalazine inhibits 5-aminoimidazole-4-carboxamidoribonucleotide (AICAR) transformylase, an enzyme involved in de novo purine biosynthesis. We recently demonstrated that methotrexate promotes intracellular AICAR accumulation, thereby increasing adenosine release and diminishing inflammation, so we tested the hypothesis that sulfasalazine similarly promotes intracellular AICAR accumulation. We studied adenosine release and the state of inflammation in in vitro and in vivo models of the inflammatory process. The adhesion of stimulated neutrophils (FMLP) to endothelial cells preincubated with sulfasalazine was inhibited in a dose-dependent manner. Elimination of extracellular adenosine by addition of adenosine deaminase or inhibition of adenosine by the adenosine A2 receptor antagonist 3,7-dimethyl-1-propargylxanthine (DMPX) completely reversed the anti-inflammatory effect of sulfasalazine (at concentrations <1 microM in this in vitro model. To determine whether this phenomenon was relevant to inhibition of inflammation in vivo, we studied the effect of sulfasalazine (100 mg/kg/day by gastric gavage for 3 days) on leukocyte accumulation in the murine air pouch model of inflammation. Treatment with sulfasalazine markedly decreased the number of leukocytes that accumulated in the inflamed (carrageenan, 2 mg/ml) air pouch. Injection of either adenosine deaminase or DMPX, but not the A1 receptor antagonist 8-cyclopentyl-dipropylxanthine, significantly reversed the anti-inflammatory effects of sulfasalazine treatment. Sulfasalazine increased the exudate adenosine concentration from 127 +/- 64 nM to 869 +/- 47 nM. Moreover, sulfasalazine treatment promoted a marked increase in splenocyte AICAR concentration from 35 +/- 6 to 96 +/- 3 pmols/10(6) splenocytes, which is consistent with the in vitro observation that sulfasalazine inhibits AICAR transformylase. These results indicate that sulfasalazine, like methotrexate, enhances adenosine release at an inflamed site and that adenosine diminishes inflammation via occupancy of A2 receptors on inflammatory cells. Our studies provide evidence that sulfasalazine and methotrexate may be described as a newly recognized family of anti-inflammatory agents that share the property of using adenosine as an antagonist of inflammation.